Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

NCT04364035 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV/AIDS

Interventions

BIOLOGICAL: ChAdOx1.HTI
BIOLOGICAL: MVA.HTI
DRUG: GS-9620
BIOLOGICAL: Placebo
DRUG: Placebo Oral Tablet

Sponsor

Aelix Therapeutics

Collaborators

[object Object]